ISRCTN14571405 https://doi.org/10.1186/ISRCTN14571405

Phase I Study: QSC301634

Submission date 16/03/2026	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol
Registration date 17/03/2026	**Overall study status** Deferred	[_] Statistical analysis plan [_] Results
Last Edited 17/03/2026	**Condition category** Other	[_] Individual participant data [X] Record updated in last year

Plain English summary of protocol
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Principal investigator

Contact name
Dr Litza McKenzie

Contact details
Mere Way, Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)1159749000
recruitment@weneedyou.co.uk

Type(s)
Public, Scientific

Contact name
Ms Jennifer Hart

Contact details
2 Davis Drive
RTP
NC
United States of America
27709

+1 (919) 597-8762
info@evecxia.com

Additional identifiers

Integrated Research Application System (IRAS)
1009011

CRO Study Code
QSC301634

Study information

Scientific Title
Phase I Trial: QSC301634
The full scientific title will be published within 30 months after the end of the trial

Study objectives
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
approved 25/02/2026, London - Brent Research Ethics Committee (2 Redman Place Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8137; brent.rec@hra.nhs.uk), ref: 26/LO/0013

Primary study design
Interventional

Allocation
Randomized controlled trial

Masking
Open (masking not used)

Control
Active

Assignment
Crossover

Purpose
Phase I study in healthy volunteers

Study type(s)

Health condition(s) or problem(s) studied

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

Completion date
16/05/2026

Eligibility

Key inclusion criteria
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Healthy volunteers allowed
Yes

Age group
Adult

Lower age limit
18 years

Upper age limit
55 years

Sex
All

Total final enrolment
0

Key exclusion criteria
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
31/03/2026

Date of final enrolment
16/05/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Quotient Sciences Limited
Mere Way, Ruddington Fields
Ruddington
Nottingham
England
NG11 6JS

Sponsor information

Organisation
Evecxia Therapeutics, Inc.

Funder(s)

Funder type

Funder Name

Evecxia Therapeutics, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available